Personensuche
Personensuche
Es wurde 1 Person gefunden.
Klinik und Poliklinik für Urologie am Universitätsklinikum Essen
Anschrift
Hufelandstraße 55
45122 Essen
45122 Essen
Telefon
E-Mail
Funktionen
-
Direktor, Klinik für Urologie
Aktuelle Veranstaltungen
-
2023 SS
Vergangene Veranstaltungen (max. 10)
-
2022 WS
-
2022 SS
-
2021 WS
-
2021 SS
-
2020 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in MenIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 4, S. 598 - 604ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
A Drop-in Gamma Probe for Minimally Invasive Sentinel Lymph Node Dissection in Prostate Cancer : Preclinical Evaluation and Interim Results From a Multicenter Clinical TrialIn: Clinical Nuclear Medicine Jg. 48 (2023) Nr. 3, S. 213 - 220ISSN: 1536-0229; 0363-9762Online Volltext: dx.doi.org/
-
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomasIn: Cancer Medicine Jg. 12 (2023) Nr. 7, S. 9041 CA Szarvas - 9054ISSN: 2045-7634Online Volltext: dx.doi.org/ (Open Access)
-
DGN-Handlungsempfehlung (S1-Leitlinie) : PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms - Stand: 01/2022 - AWMF-Registernummer: 031-055In: Nuklearmedizin = Nuclear Medicine Jg. 62 (2023) Nr. 1, S. 5 - 19ISSN: 2567-6407; 0029-5566Online Volltext: dx.doi.org/
-
Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy : A Prospective Randomized TrialIn: European Urology Oncology Jg. 6 (2023) Nr. 1, S. 49 - 55ISSN: 2588-9311Online Volltext: dx.doi.org/
-
Enfortumab Vedotin in Metastatic Urothelial Carcinoma : Survival and Safety in a European Multicenter Real-world Patient CohortIn: European Urology Open Science Jg. 53 (2023) S. 31 - 37ISSN: 2666-1683; 2666-1691Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 5, S. 711 - 716ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Immune-Checkpoint-Inhibitor Therapy : Principles and Relevance of Biomarkers for Pathologists and OncologistsIn: Advances in anatomic pathology Jg. 30 (2023) Nr. 3, S. 160 - 166ISSN: 1533-4031; 1072-4109Online Volltext: dx.doi.org/
-
Is an Endorectal Balloon Beneficial for Rectal Sparing after Spacer Implantation in Prostate Cancer Patients Treated with Hypofractionated Intensity-Modulated Proton Beam Therapy? : A Dosimetric and Radiobiological Comparison StudyIn: Current Oncology Jg. 30 (2023) Nr. 1, S. 758 - 768ISSN: 1718-7729; 1198-0052Online Volltext: dx.doi.org/ (Open Access)
-
MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer : Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 TIn: Urologia Internationalis (2023) S. 1 - 9ISSN: 0042-1138; 1423-0399Online Volltext: dx.doi.org/
-
Metastatic Prostate Cancer : A Review of Current Treatment Options and Promising New ApproachesIn: Cancers Jg. 15 (2023) Nr. 2,ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Neue Therapieansätze und Studienübersicht beim metastasierten hormonsensitiven ProstatakarzinomIn: Die Urologie (2023)ISSN: 2731-7064; 2731-7072Online Volltext: dx.doi.org/
-
Next generation radiotheranostics promoting precision medicineIn: Annals of Oncology (2023)ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/
-
Photodynamische transurethrale Resektion der Blase (TURB): mehr Schein als Sein : Ein Kommentar zur randomisierten StudieIn: Die Urologie Jg. 62 (2023) Nr. 2, S. 181 - 183ISSN: 2731-7064; 2731-7072Online Volltext: dx.doi.org/
-
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy : a systematic review and meta-analysisIn: Cancer Immunology, Immunotherapy Jg. 72 (2023) Nr. 5, S. 1061 - 1073ISSN: 1432-0851; 0340-7004Online Volltext: dx.doi.org/ (Open Access)
-
Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication PlatformIn: European Journal of Epidemiology (2023) in pressISSN: 0393-2990; 1573-7284Online Volltext: dx.doi.org/ (Open Access)
-
Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1–2 prostate cancer at MRI-targeted biopsy : a multicenter analysisIn: World Journal of Urology Jg. 41 (2023) Nr. 2, S. 427 - 434ISSN: 1433-8726; 0724-4983Online Volltext: dx.doi.org/ (Open Access)
-
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)In: European Urology Jg. 83 (2023) Nr. 5, S. 405 - 412ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ (Open Access)
-
Small Suspicious Lymph Nodes Detected on Ultrahigh-field Magnetic Resonance Imaging (MRI) in Patients with Prostate Cancer with High Risk of Nodal Metastases : The First In-patient Study on Ultrasmall Superparamagnetic Iron Oxide-enhanced 7T MRIIn: European Urology Jg. 83 (2023) Nr. 4, S. 375 - 377ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Systematische oder gezielte Fusionsbiopsie der ProstataIn: Die Urologie (2023) in pressISSN: 2731-7064; 2731-7072Online Volltext: dx.doi.org/
-
A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer : Stromal gene expressions show higher prognostic values than intrinsic tumor genesIn: International Journal of Cancer Jg. 150 (2022) Nr. 5, S. 856 - 867ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
A randomized trial of risk-adapted screening for prostate cancer in young men : Results of the first screening round of the PROBASE trialIn: International Journal of Cancer Jg. 150 (2022) Nr. 11, S. 1861 - 1869ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
Adherence to a risk-adapted screening strategy for prostate cancer : First results of the PROBASE trialIn: International Journal of Cancer (2022) in pressISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
Clinical Importance of a Peritoneal Interposition Flap to Prevent Symptomatic Lymphoceles after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection : A Systematic Review and Meta-AnalysisIn: Urologia Internationalis Jg. 106 (2022) Nr. 1, S. 28 - 34ISSN: 0042-1138; 1423-0399Online Volltext: dx.doi.org/ (Open Access)
-
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideIn: Prostate Cancer and Prostatic Diseases (2022) in pressISSN: 1365-7852; 1476-5608Online Volltext: dx.doi.org/ (Open Access)
-
Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor : a retrospective analysis of 143 patientsIn: International Urology and Nephrology Jg. 54 (2022) Nr. 1, S. 71 - 79ISSN: 1573-2584; 0301-1623Online Volltext: dx.doi.org/ (Open Access)
-
Comparative analysis of Bricker versus Wallace ureteroenteric anastomosis and identification of predictors for postoperative ureteroenteric strictureIn: Langenbeck's Archives of Surgery Jg. 407 (2022) Nr. 3, S. 1233 - 1240ISSN: 1435-2451; 1435-2443; 0023-8236Online Volltext: dx.doi.org/ (Open Access)
-
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancerIn: Journal of Cellular and Molecular Medicine Jg. 26 (2022) Nr. 4, S. 1332 - 1337ISSN: 1582-1838; 1582-4934Online Volltext: dx.doi.org/ (Open Access)
-
Correlation between symptoms and imaging findings including pelvic floor ultrasound to improve the symptom-based diagnosis of female urethral diverticulum (CHECK-UD study)In: International Urogynecology Journal Jg. 33 (2022) Nr. 8, S. 2267 - 2274ISSN: 0937-3462; 1433-3023Online Volltext: dx.doi.org/
-
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANIn: European Urology Jg. 81 (2022) Nr. 2, S. 184 - 192ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ (Open Access)
-
Diagnosis of female urethral diverticulum using pelvic floor ultrasound and comparison with voiding cystourethrogram (imaging study)In: International Urogynecology Journal (2022) in pressISSN: 0937-3462; 1433-3023Online Volltext: dx.doi.org/
-
Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacerIn: Radiation Oncology Jg. 17 (2022) Nr. 1,ISSN: 1748-717XOnline Volltext: dx.doi.org/ (Open Access)
-
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [¹⁷⁷Lu]Lu-PSMA Radioligand TherapyIn: European Urology Oncology Jg. 5 (2022) Nr. 5, S. 530 - 536ISSN: 2588-9311Online Volltext: dx.doi.org/ (Open Access)
-
Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial CarcinomaIn: Biomedicines Jg. 10 (2022) Nr. 3,ISSN: 2227-9059Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyIn: European Urology Focus (2022) in pressISSN: 2405-4569Online Volltext: dx.doi.org/ (Open Access)
-
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial CarcinomaIn: Biomedicines Jg. 10 (2022) Nr. 10,ISSN: 2227-9059Online Volltext: dx.doi.org/ (Open Access)
-
Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy : a multicenter study in German university hospitalsIn: World Journal of Urology Jg. 40 (2022) Nr. 2, S. 409 - 418ISSN: 1433-8726; 0724-4983Online Volltext: dx.doi.org/ (Open Access)
-
Impact of Surgical Experience Before Robot-assisted Partial Nephrectomy on Surgical Outcomes : A Multicenter Analysis of 2500 PatientsIn: European Urology Open Science Jg. 46 (2022) S. 45 - 52ISSN: 2666-1683; 2666-1691Online Volltext: dx.doi.org/ (Open Access)
-
Kombinierte Hormontherapie beim lokal begrenzten ProstatakarzinomIn: Die Urologie Jg. 61 (2022) Nr. 9, S. 660 - 662ISSN: 2731-7064; 2731-7072Online Volltext: dx.doi.org/
-
Lessons learned after one year of COVID-19 from a urologist and radiotherapist view : A German survey on prostate cancer diagnosis and treatmentIn: PLoS ONE Jg. 17 (2022) Nr. 6,ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 11, S. 1651 - 1658ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Onkologische Theranostik in der NuklearmedizinIn: Die Onkologie Jg. 28 (2022) Nr. 7, S. 612 - 622ISSN: 2731-7226; 2731-7234Online Volltext: dx.doi.org/
-
Onkologische Theranostik in der NuklearmedizinIn: Die Radiologie Jg. 62 (2022) Nr. 10, S. 875 - 884ISSN: 2731-7048; 2731-7056Online Volltext: dx.doi.org/
-
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC)In: Journal of Clinical Oncology (JCO) (2022)ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancerIn: Cancer Medicine (2022)ISSN: 2045-7634Online Volltext: dx.doi.org/ (Open Access)
-
Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder CancerIn: Genes Jg. 13 (2022) Nr. 3,ISSN: 2073-4425Online Volltext: dx.doi.org/ (Open Access)
-
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancerIn: International Journal of Cancer Jg. 151 (2022) Nr. 8, S. 1405 - 1419ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
Radiation Protection and Occupational Exposure on ⁶⁸Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted ProstatectomyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 9, S. 1349 - 1356ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer : A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform ProtocolIn: European Urology Jg. 81 (2022) Nr. 6, S. 621ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer : The ENACT Randomized Clinical TrialIn: European Urology Jg. 82 (2022) Nr. 5, S. 572ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Reply to Nikolaos Grivas, Nikolaos Kalampokis, Markos Karavitakis, Ioannis Leotsakos, Ioannis Katafigiotis, and Henk van der Poel’s Letter to the Editor re: Bara Barakat, Hazem Othman, Ulrich Gauger, Ingmar Wolff, Boris Hadaschik, Christian Rehme. Retzius Sparing Radical Prostatectomy Versus Robot-assisted Radical Prostatectomy: Which Technique Is More Beneficial for Prostate Cancer Patients (MASTER Study)? A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.08.003In: European Urology Focus Jg. 8 (2022) Nr. 5, S. 1556ISSN: 2405-4569Online Volltext: dx.doi.org/
-
Retrograde Pyelography in the Presence of Urothelial Bladder Cancer Does Not Affect the Risk of Upper Tract Urothelial Cancer : A Retrospective Analysis of a Single-Centre CohortIn: Urologia Internationalis Jg. 106 (2022) S. 638 - 643ISSN: 0042-1138; 1423-0399Online Volltext: dx.doi.org/ (Open Access)
-
Retzius Sparing Radical Prostatectomy Versus Robot-assisted Radical Prostatectomy : Which Technique Is More Beneficial for Prostate Cancer Patients (MASTER Study)? A Systematic Review and Meta-analysisIn: European Urology Focus Jg. 8 (2022) Nr. 4, S. 1060 - 1071ISSN: 2405-4569Online Volltext: dx.doi.org/
-
Strukturierte Befundung am Beispiel des Prostatakarzinoms : Selbstentwicklung einer digitalen Lösung für ProstatastanzbiopsienIn: Die Pathologie (2022) in pressISSN: 2731-7188; 2731-7196Online Volltext: dx.doi.org/
-
The Prognostic Value of Cytokeratin and Extracellular Collagen Expression in Urinary Bladder CancerIn: Current Molecular Medicine Jg. 22 (2022) Nr. 10, S. 941 - 949ISSN: 1875-5666; 1566-5240Online Volltext: dx.doi.org/
-
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients : A systematic review and meta-analysisIn: Prostate Cancer and Prostatic Diseases (2022) in pressISSN: 1365-7852; 1476-5608Online Volltext: dx.doi.org/ (Open Access)
-
Three-dimensional Magnetic Resonance Imaging-based Printed Models of Prostate Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Patient-tailored Radical Prostatectomy : A Feasibility StudyIn: European Urology Oncology Jg. 5 (2022) Nr. 3, S. 357 - 361ISSN: 2588-9311Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Virtual Biopsy : Just an AI Software or a Medical Procedure?In: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 4, S. 511 - 513ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Apalutamide and Overall Survival in Prostate CancerIn: European Urology Jg. 79 (2021) Nr. 1, S. 150 - 158ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ (Open Access)
-
Association of molecular subtypes with differential outcome to apalutamide treatment in nonmetastatic castration-resistant prostate cancerIn: JAMA Oncology Jg. 7 (2021) Nr. 7, S. 1005 - 1014ISSN: 2374-2445; 2374-2437Online Volltext: dx.doi.org/ (Open Access)
-
Beta radioguided surgery: towards routine implementation?In: The Quarterly Journal of Nuclear Medicine and Molecular Imaging Jg. 65 (2021) Nr. 3, S. 229 - 243ISSN: 1824-4785; 1827-1936; 0392-0208Online Volltext: dx.doi.org/
-
Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions : A Single Center ExperienceIn: Journal of Urology and Renal Diseases Jg. 6 (2021) Nr. 6,ISSN: 2575-7903Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancerIn: BJU International (BJUI) Jg. 127 (2021) Nr. 1, S. 44 - 55ISSN: 1464-410X; 1464-4096Online Volltext: dx.doi.org/
-
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 2, S. 469 - 476ISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/ (Open Access)
-
Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography–fusion BiopsyIn: European Urology Focus Jg. 7 (2021) Nr. 6, S. 1300 - 1307ISSN: 2405-4569Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatmentIn: World Journal of Urology Jg. 39 (2021) Nr. 1, S. 27 - 36ISSN: 1433-8726; 0724-4983Online Volltext: dx.doi.org/ (Open Access)
-
Die Therapie des primär oligometastasierten ProstatakarzinomsIn: Der Urologe Jg. 60 (2021) Nr. 12, S. 1527 - 1533ISSN: 1433-0563; 0340-2592; 0042-1103Online Volltext: dx.doi.org/
-
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancerIn: Nuclear Medicine and Biology Jg. 96-97 (2021) S. 101 - 111ISSN: 1872-9614; 0969-8051Online Volltext: dx.doi.org/ (Open Access)
-
Elektive Strahlentherapie pelviner Lymphknoten beim High-risk-Prostatakarzinom? : Bewertung der Relation zwischen der relativen Risikoreduktion eines PSA-Rezidivs (prostataspezifisches Antigen) innerhalb von 5 Jahren und einem absoluten ÜberlebensvorteilIn: Der Urologe Jg. 60 (2021) Nr. 8, S. 1051 - 1053.ISSN: 0340-2592; 0042-1103; 1433-0563Online Volltext: dx.doi.org/
-
Enzalutamide enhances psma expression of psma-low prostate cancerIn: International Journal of Molecular Sciences (IJMS) Jg. 22 (2021) Nr. 14,ISSN: 1422-0067; 1661-6596Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
FDG-PET avidity as a prognostic biomarker for overall survival in renal cell carcinomaIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. Suppl. 15, S. e16564ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranosticsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2021) S. 385 - 389ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
High serum pd-l1 levels are associated with poor survival in urothelial cancer patients treated with chemotherapy and immune checkpoint inhibitor therapyIn: Cancers Jg. 13 (2021) Nr. 11,ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
High-intensity focused ultrasound (HIFU) hemiablation of the prostate: Late follow-up MRI findings in non-recurrent patientsIn: European Journal of Radiology Jg. 144 (2021)ISSN: 0720-048X; 1872-7727Online Volltext: dx.doi.org/
-
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging : A Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 5, S. 675 - 678ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Implementation of radioguided surgery in prostate cancerIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging Jg. 65 (2021) Nr. 3, S. 202 - 214ISSN: 1824-4785; 1827-1936; 0392-0208Online Volltext: dx.doi.org/
-
Kann die Progression eines Prostatakarzinoms während Active Surveillance durch serielle Magnetresonanztomographie verlässlich diagnostiziert werden?In: Der Urologe Jg. 60 (2021) Nr. 12, S. 1594 - 1597ISSN: 1433-0563; 0340-2592; 0042-1103Online Volltext: dx.doi.org/
-
Lokale Strahlentherapie der Prostata mit Samenblasenbasis allein oder mit elektiver Bestrahlung pelviner Lymphknotenstationen beim Hochrisiko-Prostatakarzinom? : Ergebnisse der randomisierten POP-RT-StudieIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. 10, S. 939 - 942ISSN: 0179-7158; 1439-099XOnline Volltext: dx.doi.org/ (Open Access)
-
Lokale und Metastasen-gerichtete Therapieoptionen beim oligometastasierten ProstatakarzinomIn: Aktuelle Urologie Jg. 52 (2021) Nr. 2, S. 149 - 154ISSN: 1438-8820; 0001-7868Online Volltext: dx.doi.org/
-
M0CRPC overview of management optionsIn: World Journal of Urology Jg. 39 (2021) Nr. 2, S. 349 - 356ISSN: 1433-8726; 0724-4983Online Volltext: dx.doi.org/
-
MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer PatientsIn: Diagnostics Jg. 11 (2021) Nr. 1,ISSN: 2075-4418Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancerIn: Urologic Oncology: Seminars and Original Investigations Jg. 39 (2021) Nr. 10, S. 728.e13 - 728.e24ISSN: 1873-2496; 1078-1439Online Volltext: dx.doi.org/ (Open Access)
-
Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective studyIn: The Lancet Oncology Jg. 22 (2021) Nr. 8, S. 1115 - 1125ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/ (Open Access)
-
Nuclear medicine theranostics comes of ageIn: The Lancet Oncology Jg. 22 (2021) Nr. 11, S. 1497 - 1498ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/
-
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 4, S. 1200 - 1210ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of diseaseIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 12, S. 1747 - 1750ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
PSMA-ligand PET for early castration-resistant prostate cancer : a retrospective single-center studyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 1, S. 88 - 91ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : study protocolIn: BMC Cancer Jg. 21 (2021)ISSN: 1471-2407Online Volltext: dx.doi.org/ (Open Access)
-
Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment : A Systematic ReviewIn: European Urology Oncology Jg. 4 (2021) Nr. 5, S. 714 - 730ISSN: 2588-9311Online Volltext: dx.doi.org/
-
Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging : Utilization of a short-pass filter to reduce technical pitfallsIn: Translational Andrology and Urology Jg. 10 (2021) Nr. 10, S. 3972 - 3985ISSN: 2223-4691; 2223-4683Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient OutcomesIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 229 - 230ISSN: 2405-4569Online Volltext: dx.doi.org/
-
Prostate-specific Membrane Antigen–based Imaging of Castration-resistant Prostate CancerIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 279 - 287ISSN: 2405-4569Online Volltext: dx.doi.org/
-
Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerIn: European Urology Jg. 80 (2021) Nr. 4, S. 520 - 521ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell CarcinomaIn: European Urology Jg. 80 (2021) Nr. 2, S. 256 - 257ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Re: The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging–targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical ProstatectomyIn: European Urology Jg. 79 (2021) Nr. 1, S. 164 - 165ISSN: 1873-7560; 0302-2838; 1421-993XOnline Volltext: dx.doi.org/
-
Retroperitoneal Versus Transperitoneal Robotic Partial Nephrectomy : A Multicenter Matched-pair AnalysisIn: European Urology Focus Jg. 7 (2021) Nr. 6, S. 1363 - 1370ISSN: 2405-4569Online Volltext: dx.doi.org/
-
Stone extraction with loop ureteral catheter versus ureteroscopy in small distal ureteral stones—retrospective comparison of 547 consecutive patientsIn: Translational Andrology and Urology Jg. 10 (2021) Nr. 1, S. 87 - 95ISSN: 2223-4691; 2223-4683Online Volltext: dx.doi.org/ (Open Access)
-
Superior early and long-term continence following early micturition on day 2 after robot-assisted radical prostatectomy : A randomized prospective trialIn: World Journal of Urology Jg. 39 (2021) Nr. 3, S. 771 - 777ISSN: 1433-8726; 0724-4983Online Volltext: dx.doi.org/
-
The Biomarker Potential of Caveolin-1 in Penile CancerIn: Frontiers in Oncology Jg. 11 (2021) S. 606122ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapyIn: Urologic Oncology: Seminars and Original Investigations Jg. 39 (2021) Nr. 5, S. 296.e11 - 296.e19ISSN: 1873-2496; 1078-1439Online Volltext: dx.doi.org/ (Open Access)
-
The value of an additional scrotal suture during orchidopexyIn: Journal of Pediatric Urology Jg. 17 (2021) Nr. 1, S. 82.e1 - 82.e5ISSN: 1873-4898; 1477-5131Online Volltext: dx.doi.org/
-
Therapie des nicht-fernmetastasierten CRPC : Androgenrezeptorinhibition als neuer Therapiestandard beim nicht-fernmetastasierten kastrationsresistenten Prostatakarzinom mit hohem MetastasierungsrisikoIn: Der Urologe Jg. 60 (2021) Nr. 6, S. 753 - 759ISSN: 1433-0563; 0340-2592; 0042-1103Online Volltext: dx.doi.org/ (Open Access)
-
Transrectal Ultrasound Guided Hydrodistension : A New Surgical Way in Transgender SurgeryIn: The Journal of Sexual Medicine Jg. 18 (2021) Nr. 6, S. 1134 - 1140ISSN: 1743-6109; 1743-6095Online Volltext: dx.doi.org/
-
Zystisches Nephrom bei einem 15 Monate alten Patienten mit DICER1-MutationIn: Der Urologe Jg. 60 (2021) Nr. 6, S. 776 - 779ISSN: 0375-4685; 0340-2592; 1433-0563Online Volltext: dx.doi.org/
-
Diagnosis and Empirical Treatment of Urinary Tract Infections in Urologic OutpatientsIn: Urologia Internationalis Jg. 104 (2020) Nr. 7-8, S. 617 - 624ISSN: 0042-1138; 1423-0399Online Volltext: dx.doi.org/
-
Editorial Comment : [zu Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy]In: The Journal of Urology Jg. 204 (2020) Nr. 3, S. 510ISSN: 1527-3792; 0022-5347Online Volltext: dx.doi.org/
-
External validation of novel magnetic resonance imaging-based models for prostate cancer predictionIn: BJU International Jg. 125 (2020) Nr. 3, S. 407 - 416ISSN: 1464-4096Online Volltext: dx.doi.org/
-
First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using ⁶⁸Ga-PSMA-11In: European Journal of Nuclear Medicine and Molecular Imaging (2020)ISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/
-
Intraoperative 68Gallium-PSMA Cerenkov Luminescence Imaging for surgical margins in radical prostatectomy : A feasibility studyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 61 (2020) Nr. 10, S. 1500 - 1506ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PETIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 61 (2020) Nr. 7, S. 1037 - 1042ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate CancerIn: Advances in Therapy Jg. 37 (2020) Nr. 1, S. 512 - 526ISSN: 1865-8652; 0741-238XOnline Volltext: dx.doi.org/ (Open Access)
-
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate CancerIn: Advances in Therapy Jg. 37 (2020) S. 501 - 511ISSN: 1865-8652; 0741-238XOnline Volltext: dx.doi.org/ (Open Access)
-
Minimalinvasive Chirurgie aggressiver TumorenIn: Urologe: Organ der Deutschen Gesellschaft für Urologie (2020)ISSN: 1433-0563; 0340-2592; 0375-4685Online Volltext: dx.doi.org/
-
Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder : a randomized study in comparison with white light cystoscopyIn: World Journal of Urology Jg. 38 (2020) Nr. 6, S. 1509 - 1515ISSN: 1433-8726; 0724-4983Online Volltext: dx.doi.org/
-
Nuclear Localization of Robo is Associated with Better Survival in Bladder CancerIn: Pathology & Oncology Research Jg. 26 (2020) Nr. 1, S. 253 - 261ISSN: 1532-2807; 1219-4956Online Volltext: dx.doi.org/
-
Prevalence of APC and PTEN Alterations in Urachal CancerIn: Pathology & Oncology Research Jg. 26 (2020) Nr. 4, S. 2773 - 2781ISSN: 1532-2807; 1219-4956Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrenceIn: Current Opinion in Urology Jg. 30 (2020) Nr. 5, S. 635 - 640ISSN: 0963-0643; 1473-6586Online Volltext: dx.doi.org/
-
Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer DiagnosisIn: European Urology Jg. 78 (2020) Nr. 2, S. 291 - 292ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA) : A Prospective, Randomised, Multi-centre StudyIn: European Urology Jg. 78 (2020) Nr. 3, S. 470 - 471ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Renal duplication with ureter duplex not following Meyer-Weigert-Rule with development of a megaureter of the lower ureteral segment due to distal stenosis – A case reportIn: Urology Case Reports Jg. 28 (2020) S. 101038ISSN: 2214-4420Online Volltext: dx.doi.org/ (Open Access)
-
STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer PatientsIn: Pathology & Oncology Research Jg. 26 (2020) Nr. 2, S. 1243 - 1249ISSN: 1532-2807; 1219-4956Online Volltext: dx.doi.org/
-
Serum and tissue syndecan-1 levels in renal cell carcinomaIn: Translational Andrology and Urology Jg. 9 (2020) Nr. 3, S. 1167 - 1176ISSN: 2223-4683; 2223-4691Online Volltext: dx.doi.org/
-
Soluble syndecan-1 levels are associated with survival in platinum-treated bladder cancer patientsIn: Diagnostics Jg. 10 (2020) Nr. 11,ISSN: 2075-4418Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Therapiekonzepte beim primär oligometastasierten ProstatakarzinomIn: Der Urologe Jg. 59 (2020) Nr. 6, S. 659 - 664ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/
-
To defer or not to defer? : A German longitudinal multicentric assessment of clinical practice in urology during the COVID-19 pandemicIn: PLoS ONE Jg. 15 (2020) Nr. 9, S. e0239027ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Urachal cancer in Germany and the USA : An RKI/SEER population-based comparison studyIn: Urologia Internationalis Jg. 104 (2020) Nr. 9-10, S. 803 - 809ISSN: 0042-1138; 1423-0399Online Volltext: dx.doi.org/
-
Was erwartet der Nichtradiologe vom Radiologen?In: Der Radiologe Jg. 60 (2020) Nr. 5, S. 421 - 429ISSN: 0033-832XOnline Volltext: dx.doi.org/
-
Whole-Body Integrated [⁶⁸Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer : Comparison with Whole-Body PET/CT as the Standard of ReferenceIn: Molecular Imaging and Biology Jg. 22 (2020) Nr. 3, S. 788 - 796ISSN: 1860-2002; 1536-1632Online Volltext: dx.doi.org/
-
“TREXIT 2020” : Why the time to abandon transrectal prostate biopsy starts nowIn: Prostate Cancer and Prostatic Diseases Jg. 23 (2020) Nr. 1, S. 62 - 65ISSN: 1365-7852; 1476-5608Online Volltext: dx.doi.org/ (Open Access)
-
A Systematic Review on the Role of Imaging in Early Recurrent Prostate CancerIn: European Urology Oncology Jg. 2 (2019) Nr. 1, S. 47 - 76ISSN: 2588-9311Online Volltext: dx.doi.org/ (Open Access)
-
Active Surveillance und die moderne Diagnostik des Prostatatkarzinoms : Multiparametrische MRT, Fusionsbiopsien und neue genetische BiomarkerIn: Der Onkologe Jg. 25 (2019) Nr. 4, S. 304 - 314ISSN: 1433-0415Online Volltext: dx.doi.org/
-
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerIn: Annals of Oncology Jg. 30 (2019) Nr. 11, S. 1813 - 1820ISSN: 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinomaIn: International Journal of Cancer Jg. 145 (2019) Nr. 2, S. 531 - 539ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
Das Urachuskarzinom : Ein Update aktueller molekularer ErgebnisseIn: Der Pathologe Jg. 40 (2019) Nr. Suppl. 3, S. 239 - 243ISSN: 0172-8113Online Volltext: dx.doi.org/
-
Die Fusionsbiopsie in der Primärdiagnostik des Prostatakarzinoms : Durchführung, Nutzen und klinische AspekteIn: Der Urologe Jg. 58 (2019) Nr. 5, S. 504 - 510ISSN: 1433-0563Online Volltext: dx.doi.org/
-
Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15_Suppl, S. 5023 - 5023ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Ein neuer Androgenrezeptorantagonist : Darolutamid für Patienten mit nicht fernmetastasiertem, kastrationsresistentem ProstatakarzinomIn: Der Urologe Jg. 58 (2019) Nr. 10, S. 1217 - 1218ISSN: 0340-2592Online Volltext: dx.doi.org/
-
Erectile Dysfunction in 45-Year-Old Heterosexual German Men and Associated Lifestyle Risk Factors and Comorbidities : Results From the German Male Sex StudyIn: Sexual Medicine Jg. 7 (2019) Nr. 1, S. 26 - 34ISSN: 2050-1161Online Volltext: dx.doi.org/ (Open Access)
-
Factors Associated with Low Sexual Desire in 45-Year-Old Men : Findings from the German Male Sex-StudyIn: The Journal of Sexual Medicine Jg. 16 (2019) Nr. 7, S. 981 - 991ISSN: 1743-6109; 1743-6095Online Volltext: dx.doi.org/
-
Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective StudyIn: The Journal of Urology Jg. 202 (2019) Nr. 6, S. 1174 - 1181ISSN: 1527-3792; 0022-5347Online Volltext: dx.doi.org/
-
High soluble CGA levels are associated with poor survival in bladder cancerIn: Endocrine Connections Jg. 8 (2019) Nr. 5, S. 625 - 633ISSN: 2049-3614Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 7_Suppl, S. 42 - 42ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Molecular Imaging for Primary Staging of Prostate CancerIn: Seminars in Nuclear Medicine Jg. 49 (2019) Nr. 4, S. 271 - 279ISSN: 1558-4623; 0001-2998Online Volltext: dx.doi.org/
-
PROTEUS : A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15_Suppl, S. TPS5100 - TPS5100ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
PSA-Anstieg nach definitiver TherapieIn: Der Urologe Jg. 58 (2019) Nr. 5, S. 569 - 582ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/
-
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancerIn: Clinical Cancer Research Jg. 25 (2019) Nr. 24, S. 7448 - 7454ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/
-
Psychosocial Resources and Quality of Life in Transgender Women following Gender-Affirming SurgeryIn: The Journal of Sexual Medicine Jg. 16 (2019) Nr. 10, S. 1672 - 1680ISSN: 1743-6109; 1743-6095Online Volltext: dx.doi.org/
-
Re: Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer : A Prospective Single-Arm Clinical TrialIn: European Urology Jg. 76 (2019) Nr. 4, S. 538 - 539ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Re: Erectile dysfunction in 45-year-old heterosexual German men and associated lifestyle risk factors and comorbidities : Results from the German Male sex studyIn: The Journal of Urology Jg. 202 (2019) Nr. 4, S. 644ISSN: 1527-3792; 0022-5347Online Volltext: dx.doi.org/
-
Re: Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical CancerIn: European Urology Jg. 75 (2019) Nr. 5, S. 875ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100) : An Open-label, Dose-finding and Dose-expansion, Phase 1b TrialIn: European Urology Jg. 75 (2019) Nr. 4, S. 697 - 698ISSN: 0302-2838; 1421-993XOnline Volltext: dx.doi.org/
-
Systemtherapie des metastasierten Tumors des oberen HarntraktesIn: Der Urologe Jg. 58 (2019) Nr. 1, S. 30 - 33ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/
-
Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 7_Suppl, S. 144 - 144ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancerIn: Urologic Oncology: Seminars and Original Investigations Jg. 37 (2019) Nr. 11, S. 810.e7 - 810.e15ISSN: 1873-2496; 1078-1439Online Volltext: dx.doi.org/
-
68Ga-PSMA-11 PET/CT in prostate cancer local recurrence : impact of early images and parametric analysisIn: American Journal of Nuclear Medicine and Molecular Imaging Jg. 8 (2018) Nr. 5, S. 351 - 359ISSN: 2160-8407(Open Access)
-
Apalutamide treatment and metastasis-free survival in prostate cancerIn: The New England Journal of Medicine Jg. 378 (2018) Nr. 15, S. 1408 - 1418ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Are there limits of robotic partial nephrectomy? : TRIFECTA outcomes of open and robotic partial nephrectomy for completely endophytic renal tumorsIn: Journal of Surgical Oncology: official journal of the World Federation of Surgical Jg. 118 (2018) Nr. 1, S. 206 - 211ISSN: 0022-4790; 1096-9098Online Volltext: dx.doi.org/
-
Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder : A Comprehensive Review Supplemented by Own DataIn: Disease Markers (2018) S. 7308168ISSN: 1875-8630Online Volltext: dx.doi.org/ (Open Access)
-
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancerIn: Urologic Oncology: Seminars and Original Investigations Jg. 36 (2018) Nr. 6, S. 312.e9 - 312.e15ISSN: 1873-2496; 1078-1439Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell SubsetsIn: Clinical Cancer Research Jg. 24 (2018) Nr. 19, S. 4834 - 4844ISSN: 1078-0432; 1557-3265Online Volltext: dx.doi.org/
-
Concordance and Discordance of Sexual Identity, Sexual Experience, and Current Sexual Behavior in 45-Year-Old Men : Results From the German Male Sex-StudyIn: Sexual Medicine Jg. 6 (2018) Nr. 4, S. 282 - 290ISSN: 2050-1161Online Volltext: dx.doi.org/ (Open Access)
-
Correlation between genomic index lesions and mpMRI and ⁶⁸Ga-PSMA-PET/CT imaging features in primary prostate cancerIn: Scientific Reports Jg. 8 (2018) Nr. 1, S. 16708ISSN: 2045-2322Online Volltext: dx.doi.org/ (Open Access)
-
Discordant prostate specific antigen test results despite WHO assay standardizationIn: The International Journal of Biological Markers Jg. 33 (2018) Nr. 3, S. 275 - 282ISSN: 0393-6155; 1724-6008Online Volltext: dx.doi.org/
-
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer : an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 10, S. 1404 - 1416ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy : a prospective, randomized trialIn: World Journal of Urology Jg. 36 (2018) Nr. 11, S. 1817 - 1823ISSN: 0724-4983; 1433-8726Online Volltext: dx.doi.org/
-
Genomic features of renal cell carcinoma with venous tumor thrombusIn: Scientific Reports Jg. 8 (2018) Nr. 1, S. 7477ISSN: 2045-2322Online Volltext: dx.doi.org/ (Open Access)
-
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. 12, S. 2045 - 2054ISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/ (Open Access)
-
MRI-targeted or standard biopsy for prostate-cancer diagnosisIn: The New England Journal of Medicine Jg. 378 (2018) Nr. 19, S. 1767 - 1777ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/ (Open Access)
-
Matching-adjusted indirect comparison of the effiacy of apalutamide and enzalutamide in the treatment of non-metastatic castration-resistant prostate cancerIn: Value in Health Jg. 21 (2018) Nr. Suppl. 3, S. 20 - S21ISSN: 1524-4733; 1098-3015Online Volltext: dx.doi.org/ (Open Access)
-
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancerIn: BJU International Jg. 122 (2018) Nr. 4, S. 695 - 704ISSN: 1464-410X; 1464-4096Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancerIn: BJU International Jg. 122 (2018) Nr. 1, S. 40 - 49ISSN: 1464-410X; 1464-4096Online Volltext: dx.doi.org/ (Open Access)
-
Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancerIn: Current Opinion in Urology Jg. 28 (2018) Nr. 2, S. 172 - 177ISSN: 0963-0643; 1473-6586Online Volltext: dx.doi.org/
-
Neue Therapieoption : Apalutamid beim nicht fernmetastasierten kastrationsresistenten ProstatakarzinomIn: Der Urologe Jg. 57 (2018) Nr. 6, S. 729 - 730ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/
-
PSMA-11–Derived dual-Labeled PSMA inhibitors for preoperative PET imaging and precise fluorescence-Guided surgery of prostate cancerIn: Journal of Nuclear Medicine Jg. 59 (2018) Nr. 4, S. 639 - 645ISSN: 1535-5667; 0161-5505Online Volltext: dx.doi.org/ (Open Access)
-
Paradigmenwechsel in der Urologie : Prostatakrebsdiagnostik mittels MRT-gezielter oder konventioneller transrektaler ultraschallgesteuerter BiopsieIn: Der Urologe Jg. 57 (2018) Nr. 6, S. 727 - 728ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/
-
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomasIn: International Journal of Cancer Jg. 143 (2018) Nr. 7, S. 1764 - 1773ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused UltrasoundIn: The Journal of Urology Jg. 199 (2018) Nr. 4, S. 983 - 989ISSN: 1527-3792; 0022-5347Online Volltext: dx.doi.org/
-
Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patientsIn: BJOG: formerly: The Journal of Obstetrics and Gynaecology of the British Commonwealth / of the British Empire; British Journal of Obstetrics and Gynaecology Jg. 121 (2018) Nr. 1, S. 53 - 60ISSN: 1470-0328Online Volltext: dx.doi.org/ (Open Access)
-
Prostate cancer molecular imaging standardized evaluation (PROMISE) : Proposed miTNM classification for the interpretation of PSMA-ligand PET/CTIn: Journal of Nuclear Medicine Jg. 59 (2018) Nr. 3, S. 469 - 478ISSN: 1535-5667; 0161-5505Online Volltext: dx.doi.org/ (Open Access)
-
SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 6 Suppl., S. 161ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Sexuality after Male-to-Female Gender Affirmation SurgeryIn: BioMed Research International (2018)ISSN: 2314-6133; 2314-6141Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate CancerIn: Urologia Internationalis Jg. 101 (2018) Nr. 1, S. 65 - 73ISSN: 0042-1138; 1423-0399Online Volltext: dx.doi.org/
-
⁶⁸Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. 6, S. 904 - 912ISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/
-
68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate CancerIn: Journal of Nuclear Medicine Jg. 58 (2017) Nr. 12, S. 1949 - 1955ISSN: 0161-5505; 2159-662XOnline Volltext: dx.doi.org/
-
Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer : Patient-tailored Risk Stratification Can Reduce Unnecessary BiopsiesIn: European Urology Jg. 72 (2017) Nr. 6, S. 888 - 896ISSN: 1421-993X; 0302-2838Online Volltext: dx.doi.org/
-
Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancerIn: International Journal of Cancer Jg. 141 (2017) Nr. 8, S. 1643 - 1653ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/
-
Fokale Therapie des ProstatakarzinomsIn: Der Urologe Jg. 56 (2017) Nr. 10, S. 1335 - 1346ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/
-
Intraindividual Comparison of18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer : A Retrospective, Proof-of-Concept StudyIn: Journal of Nuclear Medicine Jg. 58 (2017) S. 1805 - 1810ISSN: 1535-5667; 0161-5505Online Volltext: dx.doi.org/
-
Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRIIn: PLoS ONE Jg. 12 (2017) Nr. 8, S. e0183329ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Multiparametric-MRI-guided biopsy in the era of precision medicineIn: Archivos Espanoles de Urologia Jg. 70 (2017) Nr. 10, S. 833 - 844ISSN: 1576-8260
-
Post-prostatectomy radiotherapy adversely affects urinary continence irrespective of radiotherapy regimeIn: World Journal of Urology Jg. 35 (2017) Nr. 12, S. 1841 - 1847ISSN: 1433-8726; 0724-4983Online Volltext: dx.doi.org/
-
Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate CancerIn: European Urology Jg. 72 (2017) Nr. 3, S. 470 - 471ISSN: 0302-2838; 1421-993XOnline Volltext: dx.doi.org/
-
The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer PredictionIn: The Journal of Urology Jg. 198 (2017) Nr. 3, S. 575 - 582ISSN: 1527-3792; 0022-5347Online Volltext: dx.doi.org/
-
Therapy assessment in prostate cancer using choline and PSMA PET/CTIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 44 (2017) Nr. Suppl. 1, S. S78 - S83ISSN: 1619-7070; 1619-7089; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/
-
Transperineal vs. transrectal biopsy in MRI targetingIn: Translational Andrology and Urology Jg. 6 (2017) Nr. 3, S. 368 - 375ISSN: 2223-4691; 2223-4683Online Volltext: dx.doi.org/ (Open Access)
-
Aktuelle Bildgebung für Urologen : Moderne Diagnostik in Praxis und KlinikIn: Der Urologe Jg. 61 (2022) Nr. 4, S. 355 - 356ISSN: 1433-0563; 0340-2592; 0042-1103Online Volltext: dx.doi.org/ (Open Access)
-
Correction to : COVID-19 research ; promising tracks leading to uro-oncologyIn: International Urology and Nephrology Jg. 53 (2021) Nr. 1, S. 95ISSN: 1573-2584; 0301-1623Online Volltext: dx.doi.org/ (Open Access)
-
Oligometastasierte und lokal fortgeschrittene urologische Tumoren : Moderne Diagnostik vor individualisierter multimodaler TherapieIn: Der Urologe Jg. 60 (2021) Nr. 12, S. 1525 - 1526ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/ (Open Access)
-
COVID-19 research : promising tracks leading to uro-oncologyIn: International Urology and Nephrology Jg. 52 (2020) Nr. 6, S. 995 - 997ISSN: 1573-2584; 0301-1623Online Volltext: dx.doi.org/ (Open Access)
-
Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. 1, S. 9 - 15ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging : The PSMA PET Progression CriteriaIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 61 (2020) Nr. 5, S. 678 - 682ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Therapie des oligo- und polytopmetastasierten ProstatakarzinomsIn: Der Urologe Jg. 59 (2020) Nr. 6, S. 657 - 658ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/ (Open Access)
-
Management des lokal begrenzten ProstatakarzinomsIn: Der Urologe Jg. 58 (2019) Nr. 5, S. 485ISSN: 1433-0563; 0340-2592Online Volltext: dx.doi.org/ (Open Access)
-
Why targeting of PSMA is a valuable adDition to the management of castration-resistant prostate cancer : The urologist's point of viewIn: Journal of Nuclear Medicine Jg. 58 (2017) Nr. 8, S. 1207 - 1209ISSN: 1535-5667; 0161-5505Online Volltext: dx.doi.org/
-
Enfortumab Vedotin bei metastasiertem Urothelkarzinom : retrospektive, multizentrische Patientenkohorte
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 64ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) : a triple tracer comparison
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine October ; 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S118 - S119ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Impact of surgical experience prior to robot-assisted partial nephrectomy on surgical outcomes : Large multicenter analysis with 2,500 patients
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S191 - S192ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ -
Inzidenz und Überleben von Patienten mit Urothelkarzinom in Nordrhein-Westfalen (NRW) : Analyse des Landeskrebsregister (LKR) von den Jahren 2008-2019
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 318ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Klinische Wirksamkeit kontemporärer Systemtherapie mit Immuntherapie beim metastasierten Urothelkarzinom, eine monozentrische Evaluation
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 318ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
2022 ASCO Genitourinary Cancers Symposium, 17.-19.02.2022, San Fransisco,In: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 40 (2022) Nr. 6, Supplement: 2022 ASCO Genitourinary Cancers Symposium,ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : An international multicenter study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S794 - S795ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S269ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. Suppl. 6,ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC) : Primary analysis of the single arm phase II trial SAKK 06/17In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 4515ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Profil der multizentrischen Kohorte der Klinischen Kommunicationsplattform des Deutschen Konsortiums für Translationale Krebsforschung (DKTK)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 13ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Risk of adverse outcomes after prostatectomy in patients diagnosed with IUSP <= 2 prostate cancer on MRI/TRUS fusion biopsy
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S438ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ -
Robot-assisted partial nephrectomy for multiple renal tumors : a multicenter analysis
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S543ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S119 - S120ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Urogenitale Sarkome im Erwachsenenalter : eine populationsbasierte Analyse von Tumorcharakteristika, Inzidenz und Überleben in Nordrhein-Westfalen (NRW)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 63ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography-fusion biopsy : A prospective, randomized comparison to conventional target biopsyIn: European Urology Jg. 79 (2021) Nr. Suppl. 1,ISSN: 1873-7560; 0302-2838
-
Development of a novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter study
EANM‘21 ; 34th Annual Congress of the European Association of Nuclear Medicine ; October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. S311 - S312ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Ga-68-versus F-18-PSMA for Cerenkov Luminescence and autoradiography in a prostate cancer mouse modelIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 17ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Initial experience from a multicentre clinical trial evaluating the safety and performance of a drop-in gamma probe for sentinel lymph node biopsy in prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 554ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET) : An explorative, multicenter studyIn: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 5066 - 5066ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Nomograms to predict outcome after LuPSMA radionuclide therapy in men with metastatic castration-resistant prostate cancer : An international multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 63 - S64ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
PRIMORDIUM : A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancerIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 676 - S677ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study ProtocolIn: Cancer Research Jg. 81 (2021) Nr. 13,ISSN: 1538-7445; 0008-5472
-
Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study protocol NCT04457245In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 6, Supplement, S. TPS172ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
The SENSEI laparoscopic tethered gamma probe for sentinel lymph node biopsy in prostate cancer : Initial experience from a multicenter clinical trialIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. Suppl. 1,ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058
-
Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC)In: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl., S. 5516ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)In: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S521ISSN: 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Mapping prostate cancer lesions pre/post unsuccessful salvage lymph node dissection employing PSMA-PETIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 61 (2020) Nr. Suppl. 1, S. 1270ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058
-
Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTANIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl.,ISSN: 0732-183X; 1527-7755
-
PSMA-PET identifies PCWG3 target populations with high concordance however superior reproducibility when compared to conventional imagingIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 61 (2020) Nr. Suppl. 1, S. 1260ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058
-
Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
ESMO Asia Virtual Congress 2020 ; 20-22 November 2020,In: Annals of Oncology Jg. 31 (2020) Nr. Supplement 6, S. S1327ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Preliminary Investigations on Radiation Exposure in [68Ga]Ga-PSMA-11 based Cerenkov Luminescence Imaging Procedures
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S212ISSN: 1619-7070; 1619-7089Online Volltext: dx.doi.org/ (Open Access) -
Abstract CT129: (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN studyIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/
-
Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTANIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 5024 - 5024ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 5025 - 5025ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN : A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii276 - viii277ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burdenIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. e17010 - e17010ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Impact of long-term androgen deprivation therapy on PSMA-ligand PET/CT in patients with castration sensitive prostate cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. Suppl. 1, S. 22 - S23ISSN: 1619-7089Online Volltext: dx.doi.org/
-
Potentially Targetable Molecular Alterations in 70 Cases of Urachal Cancer
Geared to Learn ; USCAP 107th Annual Meeting ; March 17–23, 2018, Vancouver,In: Modern Pathology Jg. 31 (2018) Nr. Suppl. 2, S. 378ISSN: 0893-3952; 1530-0285Online Volltext: dx.doi.org/ (Open Access) -
Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) : An analysis from the phase 3 SPARTAN trialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 5034 - 5034ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) : Results from the phase 3 SPARTAN trialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 5033 - 5033ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
SPARTAN, a phase 3 double-blind, randomized study of apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 43ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ (Open Access) -
Treatment of Small Renal MassesIn: Urologic Oncology / Merseburger, Axel S.; Burger, Maximilian 2019, S. 555 - 568ISBN: 9783319426235; 9783319426228Online Volltext: dx.doi.org/
-
Multiparametric MRI and MRI/TRUS Fusion Guided Biopsy for the Diagnosis of Prostate CancerIn: Molecular & Diagnostic Imaging in Prostate Cancer: Clinical Applications and Treatment Strategies / Schatten, Heide (Hrsg.) 2018, S. 87 - 98ISBN: 978-3-319-99286-0; 978-3-319-99285-3Online Volltext: dx.doi.org/